Gliclazide-d4

Gliclazide-d4

• CAS Number: 1185039-30-8
• UNSPSC Description: Gliclazide-d4 (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].
• Target Antigen: Potassium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cardiovascular Disease
• Purity: 98.0
• Solubility: 10 mM in DMSO
• Smiles: O=S(NC(NN1CC2C(CCC2)C1)=O)(C3=C([2H])C([2H])=C(C([2H])=C3[2H])C)=O
• Molecular Weight: 327.44
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Shimoyama, T., et al., Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism, 2006. 55(6): p. 722-30.|[3]Lawrence, C.L., et al., Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia, 2001. 44(8): p. 1019-25.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported